Human medicines European public assessment report (EPAR): Epclusa, sofosbuvir,velpatasvir, Hepatitis C, Chronic, Date of authorisation: 06/07/2016, Revision: 20, Status: Authorised

Epclusa is an antiviral medicine used to treat patients from 3 years of age with chronic (long-term) hepatitis C, an infectious disease that affects the liver, caused by the hepatitis C virus. Hepatitis C virus occurs in several varieties (genotypes), and Epclusa can be used to treat hepatitis C caused by all genotypes of the virus.

Epclusa contains the active substances sofosbuvir and velpatasvir.